- JP-listed companies
- Income statement
(504A) Income statement
Market cap
¥38.7B
P/E ratio
Innovacell develops cell therapy treatments for incontinence using patients' own muscle cells to restore damaged muscle function. The company has three products in clinical trials with potential first-mover advantage in this specialized field.
| 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Operating income | - | - | -1,862 | -1,873 | -2,232 |
| Income before tax | -292 | -514 | -2,001 | -2,392 | -2,854 |
| Provision for income taxes | - | - | 1 | 1 | 1 |
| Effective tax rate (%) | - | - | |||
| Net income | -1,003 | -515 | -2,002 | -2,392 | -2,855 |
| Earnings per share | -44.74 | -20.64 | -75.39 | -89.42 | -89 |